After a three-day bench trial in May, U.S. District Judge Brian Martinotti found that Sandoz lost more than $137 million in profits following the launch of the generic version of treprostinil as ...

Treprostinil is United Therapeutics' bread and butter - its four products, Tyvaso DPI (“dry powder inhaled”), nebulised Tyvaso, Remodulin, and Orenitram are all forms of the prostacyclin ...

Get detailed information on Treprostinil, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

At the moment, the only FDA-approved treatment for PH-ILD is United Therapeutics' Tyvaso inhaled prostacyclin analogue (treprostinil), which is delivered either using a nebuliser or as a DPI four ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PRINT enabled the creation of Liquidia's lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ...